Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

Incyte INCY announced that the FDA has approved the label expansion of Opzelura (ruxolitinib) cream 1.5%. Opzelura, a topical ...

Janine Tugonon's name is once again making headlines, not for pageant-related updates, but for her candid revelations about ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens ...

The U.S. Food and Drug Administration has approved Incyte's eczema cream for children aged between 2 and 11 years, the ...

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Adults with atopic dermatitis, whether diagnosed during childhood or adulthood, experienced higher rates of suicidal thoughts ...

Nektar Therapeutics (Nasdaq: NKTR) today announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, ...

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew ...

Adults who suffer from the common disorder are significantly more likely to express suicidal thoughts, concerning new ...